[Adherence, pharmacokinetic "tolerance capacity" and HIV resistance development].
Mossdorf
E
E
Klinik für Infektiologie und Spitalhygiene, Universitätsspital Basel.
Hirsch
H H
HH
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018791:CD4 Lymphocyte Count; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D004338:Drug Combinations; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D019888:Nelfinavir / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016312:Treatment Refusal; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage* / Q000493:pharmacokinetics
D044966:Anti-Retroviral Agents; D004338:Drug Combinations; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine; D019888:Nelfinavir